Neurodamage Specific Gene Discovery Service

Online Inquiry

Background Service Highlights FAQs Contact Us

Introduction: The Challenge of CAR-T-Induced Neurotoxicity

CAR-T therapy has shown impressive results in treating hematological malignancies. However, this groundbreaking immunotherapy is associated with significant adverse events, notably neurotoxicity. CAR-T-cell-associated neurotoxicity (CAR-T-NT) presents a spectrum of neurological complications, ranging from mild encephalopathy to life-threatening cerebral edema and seizures. The precise mechanisms underlying CAR-T-cell-associated neurotoxicity are still being investigated, hindering the development of effective preventative and therapeutic strategies.

The ability to predict, diagnose, and manage CAR-T-NT is crucial for maximizing the benefits of this therapy while minimizing its risks. The recent developments in genomics have identified specific genetic factors that may predispose patients to CAR-T-NT or influence its severity. Understanding the genetic basis of CAR-T-NT holds the key to personalized risk assessment, early detection, and the development of targeted interventions.

Fig.1 Toxicities in CAR-T therapy. (OA Literature) Fig.1 CAR-T therapy toxicities.¹

Our Neurodamage Specific Gene Discovery Service

Creative Biolabs offers a cutting-edge Neurodamage Specific Gene Discovery Service designed to address the critical need for improved CAR-T-NT management. This service leverages our extensive expertise in genomics, bioinformatics, and neurobiology to identify and validate genetic biomarkers associated with the development and severity of CAR-T-NT.

Service Content

Creative Biolabs' Neurodamage Specific Gene Discovery Service encompasses a comprehensive suite of methodologies:

Genome-Wide Association Studies (GWAS)

Our team is currently undertaking extensive genome-wide association studies (GWAS) to identify common genetic variants that may influence a patient's susceptibility to CAR-T-related neurotoxicity (CAR-T-NT). This involves analyzing DNA from cohorts of CAR-T-treated patients with and without neurotoxicity, using advanced statistical methods to pinpoint significant genetic associations.

Exome Sequencing

We perform whole-exome sequencing to identify rare or novel coding variants that may contribute to CAR-T-NT. This method mainly focuses on the protein-coding regions of the genome, where the majority of disease-causing mutations reside.

RNA Sequencing (RNA-Seq)

Creative Biolabs utilizes RNA-Seq to analyze gene expression profiles in relevant tissues (e.g., cerebrospinal fluid, brain biopsies, peripheral blood mononuclear cells) from CAR-T-treated patients. This provides insights into the transcriptional changes that occur during neurotoxicity and helps identify genes that are dysregulated.

Bioinformatics Analysis

Our team of expert bioinformaticians employs state-of-the-art algorithms and databases to analyze the vast amounts of genomic and transcriptomic data generated.

Functional Validation

Creative Biolabs goes beyond mere association studies. We perform functional validation experiments to confirm the role of candidate genes in CAR-T-NT.

Biomarker Identification and Validation

We use rigorous statistical methods and validation cohorts to identify robust and reliable genetic biomarkers.

Customizable Solutions

We offer customizable service packages tailored to specific project requirements, including sample processing, data analysis, and reporting.

Service Highlights

Expertise: Creative Biolabs' team includes experienced scientists who have demonstrated expertise in genomics, bioinformatics, and neurobiology.
Comprehensive Approach: Our service covers the entire spectrum of gene discovery, from initial screening to functional validation.
Data Quality: Creative Biolabs follows stringent data quality control and assurance protocols to ensure the highest standards.
Customization: Tailored solutions to meet specific research needs.

FAQs

Q1: What sample types are suitable for this service?

A1: We can work with a variety of sample types, including DNA from blood or tissue, RNA from cerebrospinal fluid (CSF), brain biopsies, and peripheral blood mononuclear cells (PBMCs).

Q2: What kind of data output is provided?

A2: We provide comprehensive reports with detailed data analysis, including variant lists, gene expression profiles, pathway analysis results, and functional validation data, all delivered in industry-standard formats.

Contact Us

Creative Biolabs is committed to advancing the understanding and management of CAR-T-NT through innovative gene discovery solutions. Please feel free to reach out to us to discuss the specifics of your project. We would be happy to explain how our expertise can help accelerate your research and contribute to improved patient outcomes.

Reference

Li, Yanping et al. "The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions." Frontiers in pharmacology vol. 13 950923. 14 Oct. 2022, doi:10.3389/fphar.2022.950923. Distributed under Open Access License CC BY 4.0, without modification.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.